

Puma Biotechnology

Earnings Call

Commercial Update



November 5, 2020


nerlynx[®]
(neratinib) tablets

Forward-Looking Safe Harbor Statement


This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements, including, but not limited to, any adverse impact on Puma’s business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma’s Annual Report on Form 10-K for the year ended December 31, 2019, Puma’s Quarterly Report on Form 10-Q for the period ended March 31, 2020, and subsequent reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.




PUMA's Pharmacy and Distributor Network



~\$49.3 Million Net NERLYNX Revenue in Q3'2020




~3,600 Ex-factory Bottles were Sold in Q3'20










Includes Commercial SP and SD

~33% of Patients in Q3'20 Started at a Reduced Dose



Rest of World Partnerships – Timelines

Region	Partner	Regulatory / Launch Milestones
Australia / SE Asia		<ul style="list-style-type: none"> March 2019 – Approved in Australia December 2019 -- Approved in Singapore Q2/Q3 2020 - Approved in Brunei, Malaysia, New Zealand
Israel		<ul style="list-style-type: none"> Q1 2020 – Launched Q3 2020- Approved in metastatic breast cancer
Canada		<ul style="list-style-type: none"> July 2019 – Approved September 2020- metastatic sNDS accepted by HC
Greater China		<ul style="list-style-type: none"> November 2019 – Approved in Hong Kong April 2020 – Approved in China August 2020 – Approved in Taiwan
Latin America		<ul style="list-style-type: none"> Q1 2020 – Argentina-Launched Q2 2020 – Approved in Chile Q3 2020 – Approved in Ecuador 2021 – Expected approvals in Brazil, Colombia, Mexico, Peru
Europe Middle East North and West Africa South Africa Turkey		<p>Launch Timelines</p> <ul style="list-style-type: none"> Q4 2019 – Germany-Launched Q4 2019 – United Kingdom-Launched Q4 2019 – Austria-Launched Q1 2020 – Sweden Launched Q1 2020 – Approved in Switzerland Q4 2020 – Planned launch in Finland
South Korea		<ul style="list-style-type: none"> October 2020 – NDA Filed

Puma Biotechnology

Earnings Call

Commercial Update



November 5, 2020

nerlynx[®]
(neratinib) tablets